217 related articles for article (PubMed ID: 30068705)
1. Local Phototherapy Synergizes with Immunoadjuvant for Treatment of Pancreatic Cancer through Induced Immunogenic Tumor Vaccine.
Zhou F; Yang J; Zhang Y; Liu M; Lang ML; Li M; Chen WR
Clin Cancer Res; 2018 Nov; 24(21):5335-5346. PubMed ID: 30068705
[No Abstract] [Full Text] [Related]
2. Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.
Kinkead HL; Hopkins A; Lutz E; Wu AA; Yarchoan M; Cruz K; Woolman S; Vithayathil T; Glickman LH; Ndubaku CO; McWhirter SM; Dubensky TW; Armstrong TD; Jaffee EM; Zaidi N
JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333318
[TBL] [Abstract][Full Text] [Related]
3. Synergistic interventional photothermal therapy and immunotherapy using an iron oxide nanoplatform for the treatment of pancreatic cancer.
Wang M; Li Y; Wang M; Liu K; Hoover AR; Li M; Towner RA; Mukherjee P; Zhou F; Qu J; Chen WR
Acta Biomater; 2022 Jan; 138():453-462. PubMed ID: 34757232
[TBL] [Abstract][Full Text] [Related]
4. Radiation and Local Anti-CD40 Generate an Effective
Yasmin-Karim S; Bruck PT; Moreau M; Kunjachan S; Chen GZ; Kumar R; Grabow S; Dougan SK; Ngwa W
Front Immunol; 2018; 9():2030. PubMed ID: 30245691
[TBL] [Abstract][Full Text] [Related]
5. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
Bauer C; Hees C; Sterzik A; Bauernfeind F; Mak'Anyengo R; Duewell P; Lehr HA; Noessner E; Wank R; Trauzold A; Endres S; Dauer M; Schnurr M
J Immunother; 2015 Apr; 38(3):116-26. PubMed ID: 25751501
[TBL] [Abstract][Full Text] [Related]
6. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
Xu C; Zhang Y; Rolfe PA; Hernández VM; Guzman W; Kradjian G; Marelli B; Qin G; Qi J; Wang H; Yu H; Tighe R; Lo KM; English JM; Radvanyi L; Lan Y
Clin Cancer Res; 2017 Oct; 23(19):5869-5880. PubMed ID: 28679778
[No Abstract] [Full Text] [Related]
8. Neutrophil infiltration and whole-cell vaccine elicited by N-dihydrogalactochitosan combined with NIR phototherapy to enhance antitumor immune response and T cell immune memory.
Qi S; Lu L; Zhou F; Chen Y; Xu M; Chen L; Yu X; Chen WR; Zhang Z
Theranostics; 2020; 10(4):1814-1832. PubMed ID: 32042338
[TBL] [Abstract][Full Text] [Related]
9. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639
[TBL] [Abstract][Full Text] [Related]
10. Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment.
Osborne N; Sundseth R; Burks J; Cao H; Liu X; Kroemer AH; Sutton L; Cato A; Smith JP
Cancer Immunol Immunother; 2019 Oct; 68(10):1635-1648. PubMed ID: 31549214
[TBL] [Abstract][Full Text] [Related]
11. The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo.
Tian Y; Li M; Yu C; Zhang R; Zhang X; Huang R; Lu L; Yuan F; Fan Y; Zhou B; Men K; Xu H; Yang L
Oncotarget; 2017 Jul; 8(28):45951-45964. PubMed ID: 28515346
[TBL] [Abstract][Full Text] [Related]
12. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.
Liu L; Wang Y; Miao L; Liu Q; Musetti S; Li J; Huang L
Mol Ther; 2018 Jan; 26(1):45-55. PubMed ID: 29258739
[TBL] [Abstract][Full Text] [Related]
13. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.
Jacobs C; Duewell P; Heckelsmiller K; Wei J; Bauernfeind F; Ellermeier J; Kisser U; Bauer CA; Dauer M; Eigler A; Maraskovsky E; Endres S; Schnurr M
Int J Cancer; 2011 Feb; 128(4):897-907. PubMed ID: 20473889
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
[TBL] [Abstract][Full Text] [Related]
15. Combination of Photodynamic Therapy and Specific Immunotherapy Efficiently Eradicates Established Tumors.
Kleinovink JW; van Driel PB; Snoeks TJ; Prokopi N; Fransen MF; Cruz LJ; Mezzanotte L; Chan A; Löwik CW; Ossendorp F
Clin Cancer Res; 2016 Mar; 22(6):1459-68. PubMed ID: 26546617
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral immunotherapy of established solid tumors with chitosan/IL-12.
Zaharoff DA; Hance KW; Rogers CJ; Schlom J; Greiner JW
J Immunother; 2010 Sep; 33(7):697-705. PubMed ID: 20664357
[TBL] [Abstract][Full Text] [Related]
17. A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.
Ma HS; Poudel B; Torres ER; Sidhom JW; Robinson TM; Christmas B; Scott B; Cruz K; Woolman S; Wall VZ; Armstrong T; Jaffee EM
Cancer Immunol Res; 2019 Mar; 7(3):428-442. PubMed ID: 30642833
[TBL] [Abstract][Full Text] [Related]
18. An Endogenous Vaccine Based on Fluorophores and Multivalent Immunoadjuvants Regulates Tumor Micro-Environment for Synergistic Photothermal and Immunotherapy.
Li L; Yang S; Song L; Zeng Y; He T; Wang N; Yu C; Yin T; Liu L; Wei X; Wu Q; Wei Y; Yang L; Gong C
Theranostics; 2018; 8(3):860-873. PubMed ID: 29344312
[TBL] [Abstract][Full Text] [Related]
19. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
20. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
